RNTX’s LTI-03 resumes phase II IPF trial after FDA hold
RNTX said LTI-03, its inhaled IPF therapy, has advanced in a global phase II trial after a temporary FDA hold was resolved, citing supportive biomarker and safety data plus funding and regulatory backing.